Monte Rosa Therapeutics, Inc. (GLUE)

Market Cap	260.19M
Revenue (ttm)	159.49M
Net Income (ttm)	6.15M
Shares Out	61.51M
EPS (ttm)	0.08
PE Ratio	54.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	872,057
Open	4.080
Previous Close	4.060
Day's Range	4.000 - 4.300
52-Week Range	3.210 - 12.400
Beta	1.52
Analysts	Buy
Price Target	14.33 (+238.77%)
Earnings Date	May 8, 2025

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 134
• Stock Exchange: NASDAQ
• Ticker Symbol: GLUE
• Website: https://www.monterosatx.com

Analyst Forecast

According to 3 analysts, the average rating for GLUE stock is "Buy." The 12-month stock price forecast is $14.33, which is an increase of 238.77% from the latest price.

Price Target

$14.33

(238.77% upside)

Analyst Consensus: Buy